XORTX Historical Cash Flow
| XRTX Stock | USD 1.33 0.06 4.72% |
Analysis of XORTX Therapeutics cash flow over time is an excellent tool to project XORTX Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 11 M or Capital Expenditures of 30.7 K as it is a great indicator of XORTX Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining XORTX Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether XORTX Therapeutics is a good buy for the upcoming year.
XORTX |
About XORTX Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in XORTX balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which XORTX's non-liquid assets can be easily converted into cash.
XORTX Therapeutics Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by XORTX Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of XORTX Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from XORTX Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into XORTX Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XORTX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.At this time, XORTX Therapeutics' Begin Period Cash Flow is fairly stable compared to the past year. Change To Account Receivables is likely to rise to 29.27 in 2024, despite the fact that Change In Cash is likely to grow to (6.6 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation | 14.0K | 55.5K | 139.7K | 146.7K | Stock Based Compensation | 396.4K | 487.9K | 121.0K | 114.9K |
XORTX Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
XORTX Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
XORTX Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (201.4K) | 112.7K | 14.7M | (3.5M) | (7.0M) | (6.6M) | |
| Free Cash Flow | (256.6K) | (742.8K) | (4.8M) | (8.9M) | (6.6M) | (6.3M) | |
| Change In Working Capital | 298.1K | 362.2K | (1.1M) | 1.4M | (1.0M) | (979.2K) | |
| Begin Period Cash Flow | 260.0K | 58.6K | 134.3K | 13.9M | 10.4M | 11.0M | |
| Other Cashflows From Financing Activities | 55.2K | (35.0K) | 1.3M | 1.4M | (295.0K) | (280.2K) | |
| Capital Expenditures | 7.0K | 14.4K | 31.2K | 44.2K | 46.4K | 30.7K | |
| Total Cash From Operating Activities | (249.6K) | (728.4K) | (4.8M) | (8.8M) | (6.6M) | (6.3M) | |
| Change To Account Receivables | 14.8K | (43.0K) | (29.2K) | (43.6K) | 27.88 | 29.27 | |
| Net Income | (629.6K) | (1.3M) | (1.3M) | (7.0M) | (2.2M) | (2.3M) | |
| Total Cash From Financing Activities | 55.2K | 855.4K | 19.2M | 4.7M | (361.0K) | (343.0K) | |
| End Period Cash Flow | 58.6K | 171.3K | 14.8M | 10.4M | 3.4M | 3.6M | |
| Stock Based Compensation | 26.3K | 230.1K | 396.4K | 487.9K | 121.0K | 114.9K | |
| Depreciation | 19.9K | 20.4K | 14.0K | 55.5K | 139.7K | 146.7K | |
| Other Non Cash Items | 1.6K | (90.2K) | 58.8K | 3.7K | (3.7M) | (3.5M) | |
| Investments | (7.0K) | (14.4K) | (39.8K) | (44.2K) | (46.4K) | (48.7K) | |
| Total Cashflows From Investing Activities | (7.0K) | (14.4K) | (39.8K) | (60.0K) | (69.0K) | (72.5K) | |
| Change To Operating Activities | (70K) | (43.0K) | (1.0M) | 762.8K | 877.2K | 921.1K | |
| Change To Netincome | 62.0K | 173.5K | (3.1M) | (4.5M) | (4.1M) | (3.9M) | |
| Change To Liabilities | 353.3K | 405.2K | (333.2K) | 1.3M | 1.5M | 1.5M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for XORTX Stock Analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.